日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Response to the commentary by Xu et al. on the PV-AIM study

对徐等人关于PV-AIM研究的评论的回应

Heidel, Florian H; Griesshammer, Martin; Kiladjian, Jean-Jacques

JAK inhibitor selection in challenging scenarios of myelofibrosis: a review

在骨髓纤维化复杂情况下选择JAK抑制剂:综述

Vachhani, Pankit; Mesa, Ruben; Mascarenhas, John; Rampal, Raajit; Oh, Stephen T; Vannucchi, Alessandro Maria; Fox, Maria Laura; Palandri, Francesca; Passamonti, Francesco; Kiladjian, Jean-Jacques; Azimi, Mahshid; Harrison, Claire; Bose, Prithviraj

Ruxolitinib treatment in patients with polycythemia vera reduces JAK2 variant allele frequency and improves symptom burden and hematocrit control

鲁索替尼治疗真性红细胞增多症患者可降低JAK2变异等位基因频率,改善症状负担并控制血细胞比容。

Harrison, Claire N; Kiladjian, Jean-Jacques; Hamer-Maansson, J E; Naim, Ahmad; Palandri, Francesca; Passamonti, Francesco

Scalable genotyping in fixed transcriptomes resolves clonal heterogeneity via single-cell sequencing

利用单细胞测序技术,在固定转录组中进行可扩展的基因分型可以解析克隆异质性。

Blattman, Sydney B; Maslah, Nabih; Varela, Austin A; Kumpaitis, Karolis; Nalbant, Benan; Snopkowski, Catherine; Mariani, Marisa; Kida, Laura C; Takizawa, Meril; Ratnayeke, Nalin; Yu, Kenny Kwok Hei; Fernandes, Sunjay; Mousavi, Nima; Borgstrom, Erik; Vallejo, Derek; Boghospor, Lorita; Xin, Ruijiao; Mignardi, Marco; Wu, Snow; Scarlott, Nicholas; Delgado-Rivera, Loruhama; Kumar, Poornasree; Krishnan, Sreenath; Giraudier, Stephane; Kiladjian, Jean-Jacques; Howitt, Brooke E; Kohlway, Andrew; Lund, Paul; Pe'er, Dana; Chaligne, Ronan; Lareau, Caleb A

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Pelabresib联合ruxolitinib治疗JAK抑制剂初治骨髓纤维化:一项随机3期试验

Rampal, Raajit K; Grosicki, Sebastian; Chraniuk, Dominik; Abruzzese, Elisabetta; Bose, Prithviraj; Gerds, Aaron T; Vannucchi, Alessandro M; Palandri, Francesca; Lee, Sung-Eun; Gupta, Vikas; Lucchesi, Alessandro; Oh, Stephen T; Kuykendall, Andrew T; Patriarca, Andrea; Álvarez-Larrán, Alberto; Mesa, Ruben; Kiladjian, Jean-Jacques; Talpaz, Moshe; Scandura, Joseph M; Lavie, David; Harris, Morgan; Kays, Sarah-Katharina; Li, Qing; Boxhammer, Rainer; Brown, Barbara; Jegg, Anna-Maria; Harrison, Claire N; Mascarenhas, John

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms

JAK2抑制介导骨髓增生性肿瘤中RAS通路突变的克隆选择

Nabih Maslah # ,Nina Kaci # ,Blandine Roux # ,Gabriela Alexe ,Raphael Marie ,Hélène Pasquer ,Emmanuelle Verger ,Rafael Daltro De Oliveira ,Cécile Culeux ,Bochra Mlayah ,Nicolas Gauthier ,Fanny Gonzales ,Lin-Pierre Zhao ,Saravanan Ganesan ,Panhong Gou ,Frank Ling ,Juliette Soret-Dulphy ,Nathalie Parquet ,William Vainchenker ,Emmanuel Raffoux ,Rose Ann Padua ,Stéphane Giraudier ,Caroline Marty ,Isabelle Plo ,Camille Lobry ,Kimberly Stegmaier ,Alexandre Puissant ,Jean-Jacques Kiladjian ,Bruno Cassinat ,Lina Benajiba

Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study

一项FIM研究评估了不适合接受强化化疗或异基因造血干细胞移植的加速期和急变期骨髓增殖性肿瘤患者接受阿扎胞苷单药或联合治疗的疗效。

Orvain, Corentin; Tavitian, Suzanne; Mediavilla, Clémence; Boyer, Françoise; Santagostino, Alberto; Venton, Geoffroy; Madene, Samia; Marchand, Tony; Turlure, Pascal; Lara, Diane; Le Clech, Lenaig; Le Du, Katell; Robin, Jean-Baptiste; Willems, Lise; Blouet, Anaïse; Systchenko, Thomas; Wemeau, Mathieu; Pasquer, Hélène; Mercier, Mélanie; Nicol, Christophe; Legros, Laurence; Machet, Antoine; Nicolini, Franck-Emmanuel; Roy, Lydia; Salvado, Clémentine; Denis, Guillaume; Lestang, Elsa; Laribi, Kamel; Luque Paz, Damien; Kiladjian, Jean-Jacques; Lippert, Eric; Benajiba, Lina; Ianotto, Jean-Christophe

Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey

患者和医生对真性红细胞增多症治疗预期和症状的看法:来自 Landmark 2.0 全球健康调查的启示

Harrison, Claire N; Ross, David M; Fogliatto, Laura Maria; Foltz, Lynda; Busque, Lambert; Xiao, Zhijian; Heidel, Florian H; Koehler, Michael; Palumbo, Giuseppe A; Breccia, Massimo; Komatsu, Norio; Kirito, Keita; Xicoy Cirici, Blanca; Martinez-Lopez, Joaquin; Rovo, Alicia; Petruk, Cheryl; Bobirca, Catalin; Mirams, Laura; McMillan, Abigail; Harper, Gavin; Kiladjian, Jean-Jacques

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV)

早期真性红细胞增多症患者的无事件生存期与对罗培南干扰素α-2b或羟基脲/最佳可用疗法的分子反应相关(PROUD-PV/CONTINUATION-PV)

Kiladjian, Jean-Jacques; Klade, Christoph; Georgiev, Pencho; Krochmalczyk, Dorota; Gercheva-Kyuchukova, Liana; Egyed, Miklos; Dulicek, Petr; Illes, Arpad; Pylypenko, Halyna; Sivcheva, Lylia; Mayer, Jiří; Yablokova, Vera; Krejcy, Kurt; Empson, Victoria; Hasselbalch, Hans C; Kralovics, Robert; Gisslinger, Heinz

Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM)

预测真性红细胞增多症患者对羟基脲治疗的耐药性:一项机器学习研究(PV-AIM)在前瞻性干预性 IV 期试验(HU-F-AIM)中得到验证

Heidel, Florian H; De Stefano, Valerio; Zaiss, Matthias; Kisro, Jens; Gückel, Eva; Großer, Susanne; Zuurman, Mike W; Manz, Kirsi; Bryan, Kenneth; Afsharinejad, Armita; Griesshammer, Martin; Kiladjian, Jean-Jacques